- Principal risks
- 6
| 5 Nov 2025 | 09:47:08 | Intention to appoint Administrator Update |
| 31 Oct 2025 | 12:15:00 | Intention to appoint Administrator |
| 30 Oct 2025 | 11:30:00 | Replacement Statement re US Subsidiary Update |
| 30 Oct 2025 | 10:38:14 | Statement re US Subsidiary Chapter 7 Update |
| 28 Oct 2025 | 17:32:24 | Update re Proposed Fundraise |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 15 Jul 2023 | Annual Report and Accounts (to 2022-12-31) | |
| 12 Apr 2022 | Annual Report and Accounts (to 2021-12-31) |
Belluscura PLC is a medical device company focused on developing and manufacturing portable oxygen concentrators, specifically the X-PLOR and the upcoming DISCOV-R. The X-PLOR is designed to deliver concentrated oxygen to patients requiring oxygen therapy and has received FDA clearance for sale in the United States and registration for sale in China. The company operates primarily in the healthcare sector, serving patients who need oxygen therapy, and has established manufacturing agreements in both the United States and China.
| 5 Nov 2025 | 09:47:08 | Intention to appoint Administrator Update |
| 31 Oct 2025 | 12:15:00 | Intention to appoint Administrator |
| 30 Oct 2025 | 11:30:00 | Replacement Statement re US Subsidiary Update |
| 30 Oct 2025 | 10:38:14 | Statement re US Subsidiary Chapter 7 Update |
| 28 Oct 2025 | 17:32:24 | Update re Proposed Fundraise |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 15 Jul 2023 | Annual Report and Accounts (to 2022-12-31) | |
| 12 Apr 2022 | Annual Report and Accounts (to 2021-12-31) |
Belluscura PLC is a medical device company focused on developing and manufacturing portable oxygen concentrators, specifically the X-PLOR and the upcoming DISCOV-R. The X-PLOR is designed to deliver concentrated oxygen to patients requiring oxygen therapy and has received FDA clearance for sale in the United States and registration for sale in China. The company operates primarily in the healthcare sector, serving patients who need oxygen therapy, and has established manufacturing agreements in both the United States and China.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £9.33bn | -0.2% | |
| £4.78bn | -0.0% | |
| £3.37bn | -0.1% | |
| £617m | +0.4% | |
| £192m | +0.1% | |
BELLBelluscura PLC | — | — |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £9.33bn | -0.2% | |
| £4.78bn | -0.0% | |
| £3.37bn | -0.1% | |
| £617m | +0.4% | |
| £192m | +0.1% | |
BELLBelluscura PLC | — | — |